Mechanistic insights into ASO-RNA complexation: Advancing antisense oligonucleotide design strategies
Oligonucleotide drugs, an emerging modulator class, hold promise for targeting previously undruggable biomacromolecules. To date, only 18 oligonucleotide drugs, including sought-after antisense oligonucleotides (ASOs) and splice-switching oligonucleotides, have approval from the U.S. Food and Drug Administration. These agents effectively bind mRNA, inducing degradation or modulating splicing. Current oligonucleotide drug design strategies prioritize full Watson-Crick base pair (bp) complementarity, overlooking mRNA target three-dimensional shapes. Given that mRNA conformational diversity can impact hybridization, incorporating mRNA key structural properties into the design may expedite ASO lead discovery. Using atomistic molecular dynamics simulations inspired by experimental data, we demonstrate the advantages of incorporating common triple bps into the design of ASOs targeting RNA hairpin motifs, which are highly accessible regions for interactions. By using an RNA pseudoknot modified into an ASO-hairpin complex, we investigate the effects of ASO length and hairpin loop mutations. Our findings suggest that ASO-mRNA complex stability is influenced by ASO length, number of common triple bps, and the dynamic accessibility of bases in the hairpin loop. Our study offers new mechanistic insights into ASO-mRNA complexation and underscores the value of pseudoknots in constructing training datasets for machine learning models aimed at designing novel ASO leads.
Authors
- Anna Reymer (ORCID: https://orcid.org/0000-0001-8458-7918)
- Johanna Hörberg (ORCID: https://orcid.org/0009-0006-7256-3859)
- Antonio Carlesso (ORCID: https://orcid.org/0000-0002-8318-7784)
Institutions
- Chalmers University of Technology (SE)
- University of Gothenburg (SE)
Publication Details
- Journal
- Molecular Therapy — Nucleic Acids
- Published
- 2024-10-04
- DOI
- https://doi.org/10.1016/j.omtn.2024.102351
- Citations
- 10
- Primary Topic
- DNA and Nucleic Acid Chemistry
- Type
- article
- Field-Weighted Citation Impact
- 2.34
Funders
- Eli Lilly and Company
- Sven och Lilly Lawskis Fond för Naturvetenskaplig Forskning
- Stiftelsen för Strategisk Forskning
- Carl Tryggers Stiftelse för Vetenskaplig Forskning
- Chalmers Tekniska Högskola
- Magnus Bergvalls Stiftelse